Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665557 | 0.96 | G6PC1 (0.47) | MAOBG6PC1GRIN1GRIN2BALDH1A1 | |
| SCHEMBL678829 | 0.94 | G6PC1 (0.50) | MAOBG6PC1GRIN1GRIN2BUSP2 | |
| SCHEMBL3249739 | 0.91 | MAOB (0.50) | MAOBG6PC1CALM1TSHR | |
| SCHEMBL676295 | 0.83 | MAOB (0.43) | MAOBG6PC1GRIN2BALDH1A1TSHR | |
| SCHEMBL9386234 | 0.82 | GBA1 (0.53) | MAOB | |
| SCHEMBL15295394 | 0.82 | MAOB (0.41) | MAOBG6PC1HPGDTSHR | |
| SCHEMBL677308 | 0.80 | G6PC1 (0.40) | MAOBG6PC1GRIN1GRIN2BALDH1A1 | |
| SCHEMBL3189709 | 0.80 | G6PC1 (0.40) | MAOBG6PC1GRIN1GRIN2BOPRM1 | |
| SCHEMBL20896988 | 0.79 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC18A2 | |
| SCHEMBL23883324 | 0.79 | MAOB (0.39) | MAOBG6PC1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | UCBBiopharma Srl (BE) | 2022-10-04 | — | — | US | disclosed |
| US-20210380573-A1 | Benzimidazolone Derivatives, and Analogues Thereof, as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-12-09 | — | — | US | disclosed |
| EP-3894003-A1 | FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2021-10-20 | — | — | EP | disclosed |
| CN-113316451-A | Benzimidazolone derivatives and analogs thereof as IL-17 modulators | UCB生物制药有限责任公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-07-29 | — | — | US | disclosed |
| WO-2020120141-A1 | FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | IL17A, IL18, IL23R | MAOB 3602/4885G6PC1 1864/4885CALM1 2883/4885 |
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | IL17A, IL18, IL23R | MAOB 3602/4885G6PC1 1864/4885CALM1 2883/4885 |
| US-20210380573-A1 | Benzimidazolone Derivatives, and Analogues Thereof, as IL-17 Modulators | IL17A, IL2, IL15 | MAOB 3185/4885G6PC1 2102/4885CALM1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.